UnitedHealthcare · CGRP mAb Subcutaneous · US health-plan appeal rights

CGRP mAb Subcutaneous denied for failing step therapy by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare CGRP mAb Subcutaneous denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: OptumRx Clinical Policy: CGRP Inhibitors / UHC Commercial Medical Benefit Drug Policy

The UnitedHealthcare angle on CGRP mAb Subcutaneous

## Why UnitedHealthcare Requires Step Therapy for CGRP Monoclonal Antibodies

UnitedHealthcare's step-therapy (also called "fail-first") policies require that patients try and fail one or more less-expensive preventive migraine treatments before UHC will approve a CGRP monoclonal antibody. The specific agents and duration of trials required are defined in UHC's Coverage Determination Guideline for this drug class and generally align with established neurology guidelines, but the exact requirements are set by UHC — not by the FDA label. Step-therapy denials are among the most common and most successfully appealed denials for this drug class, because many patients have already tried required agents, and documentation of those trials simply needs to be organized and submitted.

## Why This Denial Is Appealable

Step-therapy denials are adverse benefit determinations with full appeal rights under ACA §2719 and ERISA §503. Importantly, many states have enacted step-therapy reform laws that require insurers to grant an exception when a required step-therapy agent is contraindicated, has been previously tried and failed, or would cause clinically significant harm. Even in states without specific step-therapy statutes, the full-and-fair review standard requires UHC to consider clinical evidence that prior steps were attempted or are inappropriate. The external-review window is typically 4 months from the final internal denial, with an expedited pathway for urgent cases.

## The Appeal Process

1. Obtain UHC's current step-therapy protocol for this drug class — specifically the list of required prior agents and required trial duration. 2. Compare that list against the patient's medication and treatment history. 3. For each required agent already tried, document the trial in detail (dates, outcomes, reason for discontinuation). 4. For any required agent not tried, document the clinical reason it cannot be used (contraindication per the prescribing physician's judgment, prior intolerance, or other clinically documented barrier). 5. File a written internal appeal that addresses each step-therapy requirement in sequence. 6. If denied, escalate to external review.

## Documentation to Gather

Medication history: Pharmacy records and clinical notes documenting every preventive migraine agent previously prescribed, with start and stop dates and documented outcomes.
Prescriber's step-therapy exception letter: A letter specifically addressing each required step, confirming prior trials or explaining why untried steps are clinically inappropriate for this patient.
Diagnosis and severity documentation: Neurologist or headache-specialist notes establishing chronicity and functional impact.
State step-therapy exception law (if applicable): If your state has a step-therapy reform statute, cite it in the appeal.

## Criteria-Mapping Structure

List every step required by UHC's protocol in a numbered format. For each step, either (a) cite the chart evidence of the prior trial with dates and outcomes, or (b) cite the clinical documentation explaining why that step is not appropriate. A complete, structured response to each step is the single most effective way to win a step-therapy appeal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other insurers on CGRP mAb Subcutaneous

Other denial reasons for UnitedHealthcare CGRP mAb Subcutaneous

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.